Conference reports

Responses to TB treatment in HIV positive and HIV negative patients in the UK

800mg efavirenz may not be needed with rifampicin-based TB regimens, especially in African patients

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

Lower d4T dose maintains virologic suppression and CD4 increases

6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (IWADRLH) 26-28 October 2004, Washington

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

Nucleosides reduce PPAR-gamma: a role for rosiglitazone without thymidine analogues?

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

25% patients take Kaletra on an empty stomach: dietary advice often missed at ‘centre of excellence’

rHGH reduces central fat accumulation in adolescent lipodystrophy

Weight loss is associated with elevated PBMC proviral DNA levels

Coronary artery bypass graft is safe in HIV-positive patients but shows higher risk of longer term events

Endothelial dysfunction similar in ARV-experienced and -naive patients

Pravastatin improves lipid profiles but not endothelial function

Indinavir impairs endothelial function without insulin resistance

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

Improvement of lipids following switch to tenofovir

HCV coinfection linked to discontinuing ART due to toxicity

Restorative treatments for HIV-associated lipoatrophy

44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 30 October-2 November 2004, Washington

Tipranavir in treatment experienced patients: results from RESIST-1

Reverset: first data in patients with nucleoside resistance

Poor response with tenofovir and ddI backbone causes early study termination

Paradoxical CD4 response with tenofovir and ddI backbone

Tenofovir/FTC backbone outperforms AZT/3TC (Combivir) with efavirenz in treatment naive patients; reduced toxicity drives ITT viral efficacy

Limited stability of lopinavir/r (Kaletra) above 25°C

Atorvastatin requires dose reduction with tipranavir/r

Once-daily T-20 is less effective than twice daily: lower potency is related to C trough

Further genetic link to efavirenz absorption

Long-term response to FTC in children is similar to adults

Side effects update: hypersensitivity, heart, bones

XV International World AIDS Conference, 11-16 July 2004, Bangkok

Women and HIV: research directions

The X4 files: sampling the science on HIV co-receptors in Bangkok

10th BHIVA Autumn Conference 8-9 October 2004, London

BHIVA audit on management of HIV/Hepatitis coinfection

XV International World AIDS Conference, 11-16 July 2004, Bangkok

Dollars, commerce, politics and prejudice all present obstacles to scaling up access to treatment in resource poor countries

MTCT programmes in South Africa: nevirapine and the minister

Urgency of global access to ARV treatment for IV drug users

Replace myths with evidence–based policies on IV drug use

Adding Combivir to single dose nevirapine for reduction of MTCT significantly reduces resistance

Lopinavir/r levels reduced during pregnancy

Another chance for 3TC in patients with M184V mutation?

Kaletra monotherapy: small studies and early data

Lowering dose of d4T can maintain efficacy and reduce side effects

Three-year renal safety with tenofovir; cystatin may be a useful marker

Fluconazole increases nevirapine levels and risk of serious hepatotoxicity

Efavirenz interaction with rifampin may not require dose adjustment in patients with low body weight

Tipranavir significantly lowers doses of saquinavir, amprenavir and lopinavir/r

Responses to hepatitis vaccinations: an optimum window for protection?

HBV vaccine, CD4 count and increasing response with double-dose

Response to Hepatitis A (HAV) vaccine determined by CD4 count

Inventive ways to explain HAART and adherence to children

Isoniazid has early and unexpected benefit in reducing childhood mortality

Lack of keratin overlaying inner foreskin may explain lower HIV infection rates in circumcised men

XIII International HIV Resistance Workshop 8-12 June 2004, Tenerife

Risk of NNRTI-resistance during STI: implications for SMART and other STI studies

Persistent nevirapine resistance following mother to child transmission interventions

Tipranavir resistance and viral response: L90M did not reduce response, recommendation to use with T-20

Resistance in the UK: new approach to epidemiological studies

Low AZT activity against HIV-2 infection

No evidence for cross resistance between nevirapine and d4T

Experimental compounds to target viral expression in latent cells

Case of MDR reinfection with MDR virus

Post navigation